Year 2020 / Volume 112 / Number 7
Submission and tracking of manuscripts
Instructions to authors

Submission and tracking

REED Journal

REED Journal

Play video

Year 2020 / Volume 112 / Number 7

Original

Vedolizumab response in inflammatory bowel disease. Two years of follow-up

555-558

Pilar del Pino Bellido, María Belvis Jiménez, Luisa Castro Laria, María Belén Maldonado Pérez, Antonia Sáez Díaz, Ángel Caunedo Álvarez, Federico Argüelles-Arias,

Background: vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab. Methods: this was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between 2016 and 2019. Response and remission rates were analyzed at three, six, 12, 18 and 24 months after induction. Results: fifty-five patients were included. Clinical remission rates in CD and UC at three, six, 12, 18 and 24 months were 19.35 %, 26.67 %, 30.43 %, 30 %, 38.89 % and 29.17 %, 26.09 %, 19.05 %, 26.67 % and 20 %, respectively. Conclusions: vedolizumab is effective for induction and maintenance of clinical remission, both in Crohn’s disease and ulcerative colitis.

Valoración del lector: Valora este artículo:
Share Button
Send by e-mail

New comment


Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comments

No hay comentarios para este artículo.
Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
© 2020 The Spanish Journal of Gastroenterology